Evidence map›Paper›PMID 38094614›Full record

ArticleNigerian medical journal : journal of the Nigeria Medical Association

Clinical profile and Predictors of Outcomes of Hospitalized Patients with Laboratory-Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 in Nigeria: A Retrospective Analysis of 13 High Burden States in Nigeria.

Christopher Sabo Yilgwan, Adamu Onu, Joshua Ofoli, Longji Benle Dakum, Nathan Yakubu Shehu, Dimie Ogoina, Ijeoma Okoli, Deborah Osisanwo, Vivian Okafor, Adebola Olayinka and 2 more

Open access · greenAbstract read
In one paragraph

Article in Nigerian medical journal : journal of the Nigeria Medical Association. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 76% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Christopher Sabo YilgwanDepartment of Paediatrics, University of Jos, Jos, Nigeria.
Adamu OnuNisa Garki Hospital, Abuja, Nigeria.
Joshua OfoliNisa Premier Hospital, Alex Ekwueme way, Jabi, Abuja, Nigeria.
Longji Benle DakumDepartment of Hospital Services, Federal Ministry of Health, Abuja, Nigeria.
Nathan Yakubu ShehuWest African Center for Emerging Infectious Diseases, Jos, Nigeria.
Dimie OgoinaDepartment of Medicine, Niger Delta University, Bayelsa, Nigeria.
Ijeoma OkoliDepartment of Hospital Services, Federal Ministry of Health, Abuja, Nigeria.
Deborah OsisanwoMinistry of Health, Abeokuta, Ogun State, Nigeria.
Vivian OkaforDepartment of Hospital Services, Federal Ministry of Health, Abuja, Nigeria.
Adebola OlayinkaDepartment of Medical Microbiology, Ahmadu Bello University, Zaria, Nigeria.
Ibrahim Mamadu2 Casablanca Street, off Aminu kano crescent, Wuse 2, FCT, Abuja, Nigeria.
Adebimpe AdebiyiDepartment of Hospital Services, Federal Ministry of Health, Abuja, Nigeria.
Federal Ministry of Health · NGAhmadu Bello University · NGUniversity of Jos · NG

Funding

West African Center for Emerging Infectious DiseasesU01AI151801 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Robert W Cross, Scott C Weaver · 2020 to 2026
$10.1M
NIAID NIH HHS U01 AI151801
6 · The paper itself

Abstract

Background: The majority of global COVID deaths have occurred in developed countries. Not much is known about the clinical outcomes for the patients admitted with COVID in Nigeria. We thus described the clinical characteristics, outcomes, and predictors of outcomes of hospitalized Nigerian COVID-19 patients. Methodology: We performed multilevel and mixed effects regression, Kaplan-Meir survival, and Cox proportionate hazards analyses to evaluate factors associated with death in patients admitted for COVID-19 in 13 high-burden states of Nigeria between 25 Results: Of the 3462 patients (median age, 40 years (interquartile range 28 years 54 years), 2,990(60.6%) were male and, 213(6.15%) of them died while on admission. Male sex (adjusted odds ratio [aOR], 1.78 [95% confidence interval {CI}, 1.23-2.56]), age group 45-65 years (OR, 3.93 [95% CI, 1.29-12.02]), age group 66-75 years (aOR, 5.37 [95% CI, 1.68-17.14]), age group > 75 years (aOR, 6.81 [95% CI, 2.04-22.82]), chronic cardiac disease (aOR, 3.07 [95% CI, 1.20-7.86]), being diabetic (aOR, 2.16 [95% CI, 1.41-3.31]), and having chronic kidney disease (OR, 11.01 [95% CI, 2.74-44.24]),were strongly associated with increased odds of death. Having concurrent malaria (aOR, 0.45 [95% CI, 0.16-1.28]), use of Azithromycin for treatment (aOR, 0.33 [95% CI, 0.19-0.54]), and use of Chloroquine/Hydroxychloroquine for treatment (aOR, 0.07 [95% CI, 0.03-0.14]) were significantly associated with decreased odds of death. Conclusions: The cumulative probability of death of male patients, diabetics, hypertensives, and patients with CKD was higher than that of female patients and those without those comorbidities while concurrent malaria and use of chloroquine/hydroxychloroquine in the treatment regimen were associated with a decreased risk of dying in patients treated in our isolation centers.

Indexed as

Clinical ProfileCOVID-19High Burden StatesHospitalized PatientsNigeriaPredictors of OutcomesSARS-CoV-2

Identifiers

PMID38094614
PMCPMC10716828
OpenAlexW4389799580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.